2. Academic Validation
  3. Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives

Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives

  • Oncol Res. 2026 Feb 24;34(3):4. doi: 10.32604/or.2025.072443.
Tiffany Chen 1,  Grace Kim 2,  Yekta Rahimi 3,  Monisha Kamdar 4,  Eduardo Fernandez-Hernandez 4,  Karrune Woan 4,  Eric L Tam 4,  George Yaghmour 4
Affiliations

Affiliations

  • 1 California University of Science and Medicine, Colton, CA 92324, USA.
  • 2 Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033, USA.
  • 3 Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA 90033, USA.
  • 4 Jane Ann Nohl Division of Hematology and Center for the Study of Blood Disease, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
PMID: 41799513 DOI: 10.32604/or.2025.072443
Abstract

Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring KMT2A rearrangements (KMT2Ar) and NPM1 mutations (NPM1m). This manuscript reviews the molecular rationale of menin inhibition for aberrant homeobox/myeloid ectopic insertion site 1 (HOX/MEIS1)-driven gene expression and leukemogenesis, clinical trial outcomes, and safety data for menin inhibitors, with a focus on recently FDA-approved revumenib and several Other agents in development, ziftomenib (KO-539), bleximenib (JNJ-75276617), and icovamenib (BMF-219). We also focused our discussion on future directions to include resistance mechanisms, biomarker identification and monitoring strategies, and combination therapies. Menin inhibition is now being clinically integrated into relapsed/refractory and frontline treatment settings.

Keywords

Menin; acute myeloid leukemia (AML); bleximenib; icovamenib; leukemia; menin inhibitor; revumenib; ziftomenib.

Figures
Products